"We want to save patients with severe cancer and autoimmune diseases. We focus on immuno-oncology - the strongest growing drug segment - and benefit from well-established antibody technology to design new target drugs.", says CEO Göran Forsberg.

Cantargia AB was established in 2009/2010 and is a research-based biotechnology company engaged in research and development of antibody-based therapy against severe diseases. The company is specialised in antibody-based treatment aimed at the target molecule Interleukin-1 Receptor Accessory Protein (“IL1RAP”), which has the potential to be used against a number of different forms of cancer as well as for autoimmune and inflammatory diseases.

Cantargia's vision is to develop and safeguard a novel generation of drugs targeting IL1RAP, making the cancer treatments of tomorrow more effective. Our vision also includes the development of new drug candidates to treat autoimmune/inflammatory diseases. A new project started in 2017 with the aim of developing a new product candidate for the treatment of this type of diseases.

Cancer is one of the most common causes of death and accounts for about 20 percent of deaths in the western world. Globally, more than 14 million people are diagnosed with cancer annually and more than 8 million are losing their lives through cancer-related diseases. Despite significant advances in treatment and diagnostics, there is a great need for new treatment methods.

The original discovery made by the research team behind Cantargia was that the specific target molecule, IL1RAP, was found on cancer cells from patients with leukemia but not on normal stem cells in the bone marrow. In subsequent research Cantargia has shown that IL1RAP is also expressed on cancer cells in a large number of cancer diseases. In its most advanced project, Cantargia is developing the CAN04 antibody, which is double-acting. This means that it fights cancer both by activating the immune system and by blocking signals that drive tumour growth. During the initial development, Cantargia has chosen to focus on non-small cell lung cancer and pancreatic cancer and the clinical evaluation started in 2017.

Cantargia is listed on Nasdaq Stockholm First North since 2015 and today the company consists of 5 people, a number of consultants and partners. Cantargia is located at Medicon Village in Lund. For further information about Cantargia, see the company's website,


Chief Medical Officer - TILLSATT

Company: Cantargia AB
Position: Chief Medical Officer, part-time approximately 50%, (2-3 days/week) Reports to: CEO
Location: Home-based, Cantargia’s office is located in Lund

The position as Chief Medical Officer

We are now recruiting to a new position as Chief Medical Officer (CMO) at Cantargia. The position is a part-time assignment, approximately 50% (2-3 days/week). The CMO will report to CEO and be part of the management team.

Cantargia’s clinical programme is initially focused on non-small cell lung cancer (NSCLC) and pancreatic cancer. The first study, a ‘phase I/IIa study’, consists of two parts, with the first part evaluating the safety and tolerability of CAN04 at escalating dose levels, while the second part is designed to get an initial indication of anti-tumour activity in the chosen types of cancer. Further studies are planned, aiming at looking into mechanism of action, biomarkers and additional indications.

The CMO will be Cantargia´s medical expert and responsible for strategic development and tactical implementation of the clinical studies for our research programmes. This will include providing direct medical/physician oversight for phase I/II and proof of concept clinical trials, and clinician input into all aspects of discovery and preclinical development, from target selection to preclinical and regulatory strategy, and tactics. The ideal candidate will have a thorough understanding of the principles of oncology, pharmacology, nonclinical (toxicology), clinical and regulatory requirements for testing new therapies in humans, and experience working closely with clinical studies.

We are looking for an ambitious, self-motivated Medical Doctor (MD) with high energy and the ability and drive to develop, accomplish and follow up on different medical projects and tasks. You should have clinical experience as practicing physician with strong scientific research or clinical background in oncology. Experience from inflammation/autoimmunity is an advantage. The scope for the role is broad and requires an interest for working with many different tasks and duties. We value solid relation building skills, collaboration skills, project management skills as well as excellent presentation skills.

Main purpose of the job

• Provide medical and scientific expertise regarding Cantargia’s disease areas. Support the management team with medical expertise and contribute to the overall corporate strategy.
• Develop and update the strategy for the clinical development plan (CDP) according to corporate strategy
• Provide clinical and scientific input into Discovery Research and Early Development activities
• Contribute to the development of robust development plans for each program, including providing content for clinical development and other sections, as needed
• Identify and establish relationships with leading KOL’s and principal investigators, including organising and running KOL meetings and Advisory Boards, as needed
• Develop and update relevant parts of the Investigator’s Brochure (IB)
• Contribute to and approve protocol synopses and protocols
• Oversee clinical trials as medical expert
• Oversee, review and approve clinical study reports, as needed
• Contribute to the development of regulatory strategy and act as the medical expert in meetings with regulatory authorities
• Ensure and support effective leadership and seamless collaboration across all areas of research

Experience and qualifications

• Medical degree
• Clinical experience as practicing physician, preferably in oncology
• Strong scientific research or clinical background in oncology required. Experience from inflammation/ autoimmunity is an advantage.
• Experience from the pharmaceutical or biotech industry
• Experience in preclinical and early/late clinical development
• Experience in clinical trials, either as investigator or as industry medical representative
• Experience with regulatory activities in US and EU, as well as direct experience with IND filing
• Excellent oral and written communication skills with successful presentation capabilities, in English and preferably also in Swedish
• Computer skills (Microsoft Office)

Required skills and personal characteristics

• Maintains deep scientific knowledge and attention to detail in designing and testing hypotheses and analysing data
• Builds wide and effective networks of contacts inside and outside the organisation, across a diverse spectrum of people
• Strong ability to command respect from KOLs with a high level of personal integrity. Gathers comprehensive information to support decision making.
• Sets and develops strategies and works strategically to realise organisational goals. Identifies and develops positive and compelling visions of the organisation’s future potential.
• Deals with ambiguity, making positive use of the opportunities it presents, adapts to changing circumstances
• Works productively in a high-pressure environment and balances the demands of work and personal life
• Open minded; willing to learn and take on both “important” as well as “small” tasks and duties on different levels


The position as CMO is a part-time employment or, alternatively contracted as a consultant, approximately 50%, (2-3 days/week) and also involves traveling to e.g. meetings with researchers, KOLs, congresses and partners. Cantargia’s office is located in Lund, although the position can be home-based, in or outside of Sweden.

Opportunities with the role

Cantargia has several exciting projects in progress. Cantargia aims to develop drugs that can become an important part of the future's cancer treatment as well as in autoimmune / inflammatory diseases. You will have the opportunity to work in a small entrepreneurial pharmaceutical company, in the forefront of immuno-oncology, with research that can make a big difference for patients with e.g. non-small cell lung cancer and pancreatic cancer.


For inquires and more information about the position, please contact:

Catharina Herbertsson or Eva Runnerström, Recruitment consultants at PeakSearch.
M: +46 706 152 772

M: +46 701 725 379


Apply for the position at